GKOS – Glaukos Corporation
GKOS — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
4.82
Margin Of Safety %
Put/Call OI Ratio
0.27
EPS Next Q Diff
0.08
EPS Last/This Y
2.74
EPS This/Next Y
0.98
Price
103.15
Target Price
138.75
Analyst Recom
1.14
Performance Q
-11.54
Upside
-210.9%
Beta
0.78
Ticker: GKOS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-02 | GKOS | 121.1 | 0.57 | 0.07 | 1617 |
| 2026-03-04 | GKOS | 115.42 | 0.59 | 0.91 | 1660 |
| 2026-03-05 | GKOS | 112.07 | 0.60 | 0.16 | 1677 |
| 2026-03-09 | GKOS | 105.74 | 0.59 | 0.94 | 1689 |
| 2026-03-10 | GKOS | 103.19 | 0.56 | 2.00 | 1669 |
| 2026-03-11 | GKOS | 102.92 | 0.56 | 0.75 | 1671 |
| 2026-03-12 | GKOS | 97.77 | 0.56 | 0.00 | 1676 |
| 2026-03-17 | GKOS | 103.02 | 0.55 | 1.00 | 1700 |
| 2026-03-18 | GKOS | 103.21 | 0.54 | 0.07 | 1702 |
| 2026-03-19 | GKOS | 102.16 | 0.54 | 2.67 | 1713 |
| 2026-03-20 | GKOS | 100.99 | 0.54 | 0.35 | 1712 |
| 2026-03-23 | GKOS | 106.85 | 0.40 | 0.82 | 954 |
| 2026-03-24 | GKOS | 105.18 | 0.41 | 0.50 | 1001 |
| 2026-03-25 | GKOS | 109.57 | 0.41 | 0.00 | 1004 |
| 2026-03-26 | GKOS | 107.77 | 0.29 | 0.00 | 1297 |
| 2026-03-27 | GKOS | 103.12 | 0.27 | 0.96 | 1401 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | GKOS | 120.39 | -24.0 | 77.9 | -0.57 |
| 2026-03-02 | GKOS | 121.02 | -24.0 | 184.5 | -0.57 |
| 2026-03-03 | GKOS | 117.88 | -24.0 | 184.6 | -0.57 |
| 2026-03-04 | GKOS | 115.35 | -24.0 | 184.6 | -0.57 |
| 2026-03-05 | GKOS | 112.08 | -24.0 | 184.6 | -0.57 |
| 2026-03-06 | GKOS | 107.71 | -24.0 | 184.7 | -0.57 |
| 2026-03-09 | GKOS | 105.69 | -24.0 | 184.6 | -0.57 |
| 2026-03-10 | GKOS | 103.25 | -24.0 | 184.6 | -0.57 |
| 2026-03-11 | GKOS | 102.83 | -24.0 | 184.5 | -0.57 |
| 2026-03-12 | GKOS | 97.75 | -24.0 | 184.7 | -0.57 |
| 2026-03-13 | GKOS | 97.02 | -24.0 | 184.6 | -0.57 |
| 2026-03-17 | GKOS | 103.02 | -24.0 | 184.4 | -0.57 |
| 2026-03-18 | GKOS | 103.25 | -24.0 | 184.5 | -0.57 |
| 2026-03-19 | GKOS | 102.08 | -24.0 | 184.9 | -0.57 |
| 2026-03-20 | GKOS | 100.89 | -20.8 | 184.9 | -0.56 |
| 2026-03-23 | GKOS | 106.86 | -20.8 | 184.7 | -0.56 |
| 2026-03-24 | GKOS | 105.23 | -20.8 | 184.8 | -0.56 |
| 2026-03-25 | GKOS | 109.54 | -20.8 | 184.6 | -0.56 |
| 2026-03-26 | GKOS | 107.83 | -20.8 | 184.7 | -0.56 |
| 2026-03-27 | GKOS | 103.15 | -23.6 | 184.8 | -0.54 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | GKOS | -11.82 | -0.48 | 4.87 |
| 2026-03-02 | GKOS | -11.82 | 0.69 | 4.87 |
| 2026-03-03 | GKOS | -11.82 | 0.69 | 4.87 |
| 2026-03-04 | GKOS | -11.82 | 0.69 | 4.87 |
| 2026-03-05 | GKOS | -11.82 | 0.69 | 4.87 |
| 2026-03-06 | GKOS | -11.82 | 0.69 | 4.87 |
| 2026-03-09 | GKOS | -11.82 | 0.60 | 4.87 |
| 2026-03-10 | GKOS | -11.82 | 0.60 | 4.87 |
| 2026-03-11 | GKOS | -11.82 | 0.60 | 5.18 |
| 2026-03-12 | GKOS | -11.82 | 0.60 | 5.18 |
| 2026-03-13 | GKOS | -11.67 | 0.60 | 5.18 |
| 2026-03-17 | GKOS | -11.67 | 2.99 | 5.18 |
| 2026-03-18 | GKOS | -11.67 | 2.99 | 5.18 |
| 2026-03-19 | GKOS | -11.72 | 2.99 | 5.18 |
| 2026-03-20 | GKOS | -11.72 | 2.99 | 5.18 |
| 2026-03-23 | GKOS | -11.72 | 2.99 | 5.18 |
| 2026-03-24 | GKOS | -11.72 | 2.99 | 5.18 |
| 2026-03-25 | GKOS | -11.70 | 2.99 | 4.82 |
| 2026-03-26 | GKOS | -11.75 | 2.99 | 4.82 |
| 2026-03-27 | GKOS | -11.75 | 2.99 | 4.82 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.28
Avg. EPS Est. Current Quarter
-0.27
Avg. EPS Est. Next Quarter
-0.2
Insider Transactions
-11.75
Institutional Transactions
2.99
Beta
0.78
Average Sales Estimate Current Quarter
136
Average Sales Estimate Next Quarter
144
Fair Value
Quality Score
44
Growth Score
50
Sentiment Score
93
Actual DrawDown %
37
Max Drawdown 5-Year %
-64.3
Target Price
138.75
P/E
Forward P/E
237.85
PEG
P/S
11.81
P/B
9.04
P/Free Cash Flow
EPS
-3.27
Average EPS Est. Cur. Y
-0.54
EPS Next Y. (Est.)
0.44
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-36.99
Relative Volume
0.8
Return on Equity vs Sector %
-56
Return on Equity vs Industry %
-40.4
EPS 1 7Days Diff
EPS 1 30Days Diff
0.03
EBIT Estimation
184.8
◆
GKOS
Healthcare
$103.18
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
43.5
Range 1M
31.9%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
39.7%
EPS NY
179.9%
52W%
54%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-50.9% upside
Upside
-50.9%
Quality
44
Glaukos CorporationSector: Healthcare
Industry: Medical Devices
Employees: 1094
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
GKOS
Latest News
—
Caricamento notizie per GKOS…
stock quote shares GKOS – Glaukos Corporation Stock Price stock today
news today GKOS – Glaukos Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch GKOS – Glaukos Corporation yahoo finance google finance
stock history GKOS – Glaukos Corporation invest stock market
stock prices GKOS premarket after hours
ticker GKOS fair value insiders trading